

Time	Agenda item	Presenter
Session 1: Opening session		
08:45 – 09:00	Registration and morning coffee	All
09:00 - 09:30	Welcome and opening remarks	Haile Getahun Director a.i., GCP AMR Division, WHO Peter Beyer , Senior Advisor AMR Division, WHO
	Round of introductions and nomination of Chair	All
09:30 - 09:45	Conflict of interest management	Sarah Paulin Technical Officer AMR Division, WHO
09:45 – 10:00	Overview of WHO’s work on R&D priority setting for AMR	Peter Beyer
Session 2: 2019 Clinical antibacterial pipeline update		
10:00 – 12:00	Antibiotics and combinations containing a new chemical entity for treatment of priority pathogens (changes/additions since last revision): <ul style="list-style-type: none"> FDA approved since last revision NDA Phase 3 Phase 2 New Phase 1 	Ursula Theuretzbacher , Consultant AMR Division, WHO
	Validation and discussion on changes and update	All
12:00 – 13:00	Lunch	All

Session 3: Country insight from Russia		
13:00-13:30	Overview of the antibacterial R&D landscape in Russia	Roman Kozlov Professor Institute of Antimicrobial Chemotherapy, Russia
Session 4: 2019 Clinical antibacterial pipeline update		
13:30 - 17:00	<p>Clinical pipeline changes and additions since the last revision:</p> <ul style="list-style-type: none"> • Antibiotics and combinations containing a new chemical entity for treatment of priority pathogens (cont.) • Antibiotics for the treatment of TB • Antibiotics for the treatment for <i>C. difficile</i> infections • Biological antibacterial agents targeting priority pathogens, TB and <i>C. difficile</i> <p>Validation and discussion on changes and update</p>	<p>Ursula Theuretzbacher</p> <p>All</p>
17:00	End of day 1	
17:30 – 20:00	Informal Dinner	Restaurant La Fontaine Chemin Palud 2, 1292 Pregny-Chambésy

Day 2 – 1 October 2019

Time	Agenda item	Presenter
Session 5: 2019 Clinical antibacterial pipeline update and methodology		
09:00 – 10:00	Finalization of 2019 clinical antibacterial pipeline: discussion and consensus	Peter Beyer and Sarah Paulin
10:00 – 11:30	Discussion for way forward: <ul style="list-style-type: none">• Need for changes to the methodology/ alignment with TPPs• Innovation criteria• Scope expansion to non-trationals• Advice on GARDP portfolio expansion	
Session 6: Country insight from Japan		
11:30 - 12:00	Overview of the antibacterial R&D landscape in Japan	Norio Ohmagari Professor National Center for Global Health and Medicine, Japan
12:00 - 13:00	Lunch	All
Session 7: Pre-clinical pipeline and closing		
13:00 - 14:45	Presentation of WHO’s 1 st pre-clinical pipeline review	Sarah Paulin and Richard Alm, Consultant AMR Division, WHO
	Comments on key findings from draft journal publication	Ursula Theuretzbacher
	Discussion	All
14:45 - 15:00	Way Forward and Closing Remarks	Peter Beyer
15:00	End of the meeting	